BMS Secures Phase 3 Wins for Admilparant and RYZ101 Amid Patent Cliff Pressures

Key points

• Admilparant, an LPA1 antagonist for idiopathic pulmonary fibrosis (IPF), met its primary endpoint at the 60 mg dose, showing significant improvement in lung function at Week 52, though the 120 mg dose failed to reach statistical significance.
• RYZ101, a radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), demonstrated significantly longer progression-free survival compared to standard care in patients who had progressed on Lutetium-177 therapy.
• BMS plans to engage with regulators regarding approval for both drugs, aiming to establish them as growth drivers before Eliquis and Opdivo lose U.S. market exclusivity in 2028.
• Safety concerns persist for admilparant, including a case of acute liver injury in the 120 mg arm, though BMS management indicated the event was unlikely related to the study treatment.
• Investor sentiment was volatile; BMS shares rose 3.5% at the open but fell 3% by the end of the day, while Contineum Therapeutics shares surged 27% on the news.

Background

BMS faces significant revenue pressure as its cornerstone drugs, Eliquis and Opdivo, approach patent cliffs in 2028. The company has attempted to diversify through acquisitions, such as the $14 billion purchase of Karuna Therapeutics for the schizophrenia drug Cobenfy, but this asset has yet to contribute significantly to revenue. These recent Phase 3 successes are critical steps in BMS's strategy to secure post-patent growth. The broader biotech landscape has seen increased focus on solid tumor treatments, as evidenced by recent advancements in CAR T-cell therapies and mRNA vaccines, though BMS's approach utilizes distinct mechanisms like LPA1 antagonism and alpha-emitter radiopharmaceuticals.

How outlets are covering it

Fierce Biotech highlights the mixed nature of the results, noting that while both trials hit primary endpoints, doubts remain regarding dose response and safety. The outlet emphasizes that the 120 mg dose of admilparant failed to clear the statistical bar and that BMS has not yet shared detailed data. Yahoo Finance focuses on the market impact, specifically the 27% surge in Contineum Therapeutics shares, suggesting a broader positive reception for the pipeline despite BMS's own stock volatility. Analysts from William Blair and Guggenheim Securities, cited by Fierce Biotech, view the 60 mg success as a potential blockbuster opportunity, estimating sales of $1.3 billion for IPF by 2032, while acknowledging lingering questions about the magnitude of benefit.

Why it matters

These results are pivotal for BMS as it navigates a period of declining revenue from its most profitable drugs. Success in these trials could provide new, high-growth revenue streams in the respiratory and oncology sectors. However, the mixed market reaction and unresolved safety questions indicate that the path to long-term growth remains uncertain, requiring careful regulatory navigation and further data disclosure to reassure investors.

What to watch

BMS intends to discuss the next steps with the FDA regarding regulatory submissions for both admilparant and RYZ101. The company has not yet released detailed data from the trials, which will be crucial for addressing safety concerns and dose-response questions. Investors will likely watch for further updates on the phase 3 Librexia AF trial of milvexian, another key drug in BMS's pipeline, as well as any regulatory decisions or data releases from the current trials.